Australia's Neuren Pharmaceuticals hits one-year high on DAYBUE sales jump

** Shares of Neuren Pharmaceuticals NEU.AX rise as much as 8.4% to A$18.440, their highest level since August 2, 2024

** The drug developer says its North American partner Acadia Pharmaceuticals ACAD.O posts Q2 net sales of $96.1 million for DAYBUE™ (trofinetide), up 14% from a year ago

** The drug is used to treat genetic brain disorders like Rett syndrome

** Neuren anticipates Q2 royalties of A$14.7 million ($9.57 million) from DAYBUE sales, a 16% jump

** Co has granted Acadia exclusive license for the development and commercialisation of DAYBUE (trofinetide)

** YTD, NEU shares up 44.2%, ACAD shares up 29.7%

($1 = 1.5363 Australian dollars)